Status:
NOT_YET_RECRUITING
Evaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological Malignancies
Lead Sponsor:
University Hospital, Angers
Conditions:
Acute Myeloid Leukemia
Hodgkin's Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
Chemotherapy-induced cognitive disorders, such as memory problems, slowness of execution, inability to concentrate, and language difficulties, are sequelae that occur in patients undergoing chemothera...
Eligibility Criteria
Inclusion
- Patient group inclusion criteria:
- adult patient with acute myeloid leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma;
- patient receiving a fixed-duration first-line chemotherapy;
- patient affiliated or beneficiary of a social security scheme; .signed inform consent form.
- Control group inclusion criteria:
- adult;
- patient's relative (spouse, brother, sister, friend, etc.);
- less than 5 years of difference with the patient;
- same educational level (\< baccalaureate/high school degree, baccalaureate/high school degree level, 2-year university degree, \> 2-year university degree);
- person affiliated or beneficiary of a social security scheme;
- signed informed consent form
Exclusion
- Patient group exclusion criteria:
- no patient's relative for the control group;
- known or suspective cognitive disorders prior to chemotherapy;
- history of severe neurological or psychiatric disorders (e.g., severe depression); .previous chemotherapy;
- previous brain radiotherapy;
- ongoing treatments affecting cognition;
- patient unable to read;
- patient not speaking French;
- person deprived of liberty by judicial or administrative decision;
- person under forced psychiatric care;
- person under legal protection measures;
- person unable to express consent; .pregnant or breastfeeding woman.
- Control group exclusion criteria:
- known or suspected cognitive disorders;
- history of severe neurological or psychiatric disorder (e.g., severe depression); .previous chemotherapy;
- previous brain radiotherapy;
- ongoing treatments affecting cognition;
- person unable to read;
- person not speaking French;
- person deprived of liberty by judicial or administrative decision;
- person under forced psychiatric care;
- person under legal protection measures;
- person unable to express consent;
- pregnant or breastfeeding woman."
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2027
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT07147621
Start Date
October 1 2025
End Date
October 1 2027
Last Update
August 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Angers
Angers, Maine et Loire, France, 49933